Knowledge Graph · Medication
Tirzepatide
A dual GIP and GLP-1 receptor agonist for type 2 diabetes and obesity.
Authoritative sources
Evidence base
Randomized Controlled Trial · 2022 · Landmark
Tirzepatide Once Weekly for the Treatment of Obesity
New England Journal of Medicine · Jastreboff AM, Aronne LJ, Ahmad NN, et al. (SURMOUNT-1)
The pivotal trial that established tirzepatide (Zepbound / Mounjaro) as the most effective medication studied for weight loss to date.
Where Tirzepatide appears on Kindr Health
Data hub
Wiki
This page is part of Kindr Health's public Knowledge Graph. Content is for educational purposes only and is not medical advice.